Sievers, Quinlan L.Petzold, GeorgBunker, Richard D.Renneville, AlineSlabicki, MikolajLiddicoat, Brian J.Abdulrahman, WassimMikkelsen, TarjeiEbert, BenjaminThomä, Nicolas H.2022-08-252018-11-02Sievers, Quinlan L., Georg Petzold, Richard D. Bunker, Aline Renneville, Mikolaj Slabicki, Brian J. Liddicoat, Wassim Abdulrahman et al. "Defining the Human C2H2 Zinc Finger Degrome Targeted by Thalidomide Analogs Through CRBN." Science 362, no. 6414 (2018): eaat0572. DOI: 10.1126/science.aat05720036-80751095-9203https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37373052The small molecules thalidomide, lenalidomide, and pomalidomide induce the ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) by recruiting a Cys2-His2 (C2H2) zinc finger domain to Cereblon (CRBN), the substrate receptor of the CRL4CRBN E3 ubiquitin ligase. Here we screened the human C2H2 zinc finger proteome for degradation in the presence of thalidomide analogs, identifying 11 zinc finger degrons. Structural and functional characterization of the C2H2 zinc finger degrons demonstrates how diverse zinc finger domains bind the permissive drug-CRBN interface. Computational zinc finger docking and biochemical analysis predict that more than 150 zinc fingers bind the drug-CRBN complex in vitro, a larger number than previously anticipated, and we show that selective zinc finger degradation can be achieved through compound modifications. Our results provide a rationale for therapeutically targeting transcription factors that were previously considered undruggable.en-USResearch Subject Categories::MEDICINE::Chemistry::BiochemistryResearch Subject Categories::MEDICINE::Physiology and pharmacology::Pharmacological researchJournal Article2018-07-0920182022-08-2510.1126/science.aat0572